NCT05566600View on ClinicalTrials.gov

Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 9, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

July 31, 2025

Conditions
Ischemic Heart FailureChronic Heart Failure
Interventions
BIOLOGICAL

Human (allogeneic) iPS-cell-derived cardiomyocyte

10-20 epicardial injections (0.25 mL each) of iPSC-CMs will be delivered in the border zone of the infarcted myocardium

Trial Locations (2)

210000

NOT_YET_RECRUITING

HelpThera, Nanjing

410000

RECRUITING

The second xiangya hospital of central south university, Changsha

Sponsors

Lead Sponsor

Help Therapeutics
All Listed Sponsors
collaborator

Central South University

OTHER

lead

Help Therapeutics

INDUSTRY